论文部分内容阅读
目的研究安体舒通对慢性胆总管结扎肝硬化犬门脉压力和门体分流的作用。方法用门静脉插管直接测压和９９ｍＴｃ－ＭＩＢＩ心肝放射性摄取比值（Ｈ／Ｌ）来评价安体舒通的作用。安体舒通口服每日２０ｍｇ／ｋｇ，连续四周。结果四周后１６只犬中１３只犬完成了研究。门脉压力从２５８７２±０．５０９６ｋＰａ下降为２４２０６±０．４７０４ｋＰａ（ｐ＜０．０５），Ｈ／Ｌ值从０３３±０．０６下降为０３０±０．０８（ｐ＜０．０５）。伴血浆容量明显减少，肝血流量无明显变化。结论安体舒通能降低肝硬化犬的门脉压力和门体分流，是治疗门脉高压的的有效药物。
Objective To investigate the effect of spironolactone on portal pressure and portal shunt in dogs with chronic common bile duct ligation of liver cirrhosis. Methods The effect of spironolactone was evaluated by direct manometry of portal vein catheterization and ratio of radioactive uptake of 99mTc-MIBI to heart and liver (H / L). Spironolactone daily oral 2 0mg / kg, for four weeks. Results After four weeks, 13 dogs from 16 dogs completed the study. The portal pressure decreased from 25872 ± 0.5096kPa to 24206 ± 0.4704kPa (p <0.05), and the H / L decreased from033 ± 0.06 to030 ± 0.08 (p < p <0.05). With a significant reduction in plasma volume, no significant changes in liver blood flow. Conclusion spironolactone can reduce portal hypertension and portosystemic shunt, is an effective drug for the treatment of portal hypertension.